Form 4: Pulse Biosciences Director Receives Stock Option Grant

Director Richard van den Broek was granted 38,423 stock options in Pulse Biosciences, Inc. as part of a compensation update.

Summary

• Director Richard van den Broek received a grant of 38,423 stock options on June 11, 2026.
• The options have an exercise price of $26.89 per share.
• The grant is split into two tranches: 30,000 options vesting monthly over one year and 8,423 options vesting quarterly over one year.
• The options expire on June 11, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market price volatility could impact the value of the options and the incentive structure for the director.

Future Outlook

The options vest over a one-year period, contingent upon the director's continued service to the company.

Management Comments

• No specific management commentary provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice to ensure alignment between board members and shareholders, particularly in the biotechnology sector where long-term development cycles are common.

Comparison to Industry Standards

• The use of time-based vesting (monthly and quarterly) is consistent with standard executive and director compensation packages in the U.S. biotech industry.
• The 10-year expiration term is a standard market practice for non-qualified stock options.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the first tranche of options on July 11, 2026.
• Vesting of the second tranche of options on September 5, 2026.

Key Dates

Keywords

Pulse Biosciences, PLSE, Form 4, Insider Trading, Stock Options, Director Compensation